Stem Cell Therapies for Cardiovascular and Metabolic Disorders Markets, 2012-2018 & 2019-2030 – ResearchAndMarkets.com

Cell Therapies for Cardiovascular and Metabolic Disorders, 2019-2030”

report has been added to ResearchAndMarkets.com’s

The Stem Cell Therapies for Cardiovascular & Metabolic Disorders,
2019-2030 report features an extensive study of the current market
landscape and the future potential of stem cell therapies in treating
the aforementioned clinical conditions.

The study includes all stem cell therapies that are being developed for
the treatment of cardiovascular and metabolic disorders. In addition, we
have provided a list of stem cell therapies being developed for stroke,
a condition associated with vasculature in the brain.

Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of stem cell
    therapies with respect to target therapeutic area (cardiovascular and
    metabolic), phase of development (approved, phase III, phase II, phase
    I and preclinical / discovery), target disease indications
    (Cardiovascular: heart failure, myocardial infarction, critical limb
    ischemia, angina, peripheral arterial / vascular diseases, myocardial
    ischemia, myocardial fibrosis, cardiomyopathy and coronary
    microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis
    type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic
    leukodystrophy), source of cells (autologous and allogenic), type of
    stem cells (adult multipotent, adult pluripotent, embryonic
    multipotent, embryonic pluripotent and others), stem cell lineage
    (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle,
    Wharton’s jelly, umbilical cord, placenta, dental pulp, cord blood and
    pancreas), and route of administration (intramyocardial,
    intramuscular, intravenous, intracoronary, subcutaneous implantation
    and surgical implantation).
  • An analysis highlighting the key unmet needs across cardiovascular and
    metabolic disorders, featuring insights generated from social media
    posts, recent scientific publications, patient blogs and the views of
    contemporary key opinion leaders as expressed on online platforms.
  • An overview of the focus areas of therapy developers, including an
    assessment of the existing opportunity for stem cell therapies across
    diverse therapeutic indications.
  • An insightful company competitiveness analysis featuring a
    three-dimensional bubble representation, highlighting the key players
    in this domain on the basis of the strength of their respective
    product portfolios, taking into consideration the number of therapies
    under development, phase of development of these therapies, number of
    disease indications being targeted and geographical distribution of
    affiliated clinical trials.
  • An analysis of the partnerships that have been established in the
    domain in the period 2012-2018, covering R&D collaborations, licensing
    agreements, mergers and acquisitions, product development and/or
    commercialization agreements, manufacturing agreements, clinical trial
    agreements, process development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development
    in companies that are focused in this area, including seed financing,
    venture capital financing, capital raised from IPOs / secondary
    offerings, debt financing and grants.
  • An analysis of contemporary peer-reviewed scientific research articles
    published during the period 2013-2018, highlighting the key focus
    areas of the ongoing research activity, in terms of therapeutic area,
    target disease indication, and source of cells.
  • Comprehensive profiles of approved and late-stage clinical products;
    each profile features an overview of the therapy, its mechanism of
    action, history of development, current development status, key
    clinical trial results, details on recommended dose, price and
    manufacturing process (wherever available).
  • One of the key objectives of the report was to understand the primary
    growth drivers and estimate the future size of the market. Based on
    parameters, such as target consumer segments, likely adoption rates
    and expected pricing, we have provided an informed estimate of the
    likely evolution of the market in the short to mid-term and long term,
    for the period 2019-2030.
  • The report includes information on (potential) sales-based revenues
    generated by stem cell therapies that are currently marketed or are in
    late stages of development for the treatment of cardiovascular and
    metabolic disorders. Additionally, it presents details on the likely
    distribution of the current and forecasted opportunity across [A]
    target therapeutic areas (cardiovascular and metabolic), [B] target
    disease indications (myocardial ischemia, heart failure, critical limb
    ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other
    cardiovascular and metabolic disorders ), [C] type of stem cells
    (adult multipotent, adult pluripotent and embryonic multipotent), [D]
    source of cells (autologous and allogenic), [E] stem cell lineage
    (bone marrow, peripheral blood and others), [F] route of
    administration (intramyocardial, intracoronary, intramuscular,
    intravenous and surgical implantation) and [G] key geographical
    regions (North America, Europe and Asia Pacific). To account for the
    uncertainties associated with the development of novel therapy
    products and to add robustness to our model, we have provided three
    forecast scenarios, portraying the conservative, base and optimistic
    tracks of the market’s evolution.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Unmet Need Analysis

6. Key Therapeutic Areas

7. Company Competitiveness Analysis

8. Partnerships And Collaborations

9. Funding And Investment Analysis

10. Publication Analysis

11. Stem Cell Therapies For Cardiovascular Disorders: Therapy Profiles

12. Stem Cell Therapies For Metabolic Disorders: Therapy Profiles

13. Market Forecast

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/r/9oaflt


Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Stem

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.